LONG-TERM ADMINISTRATION OF META-CHLOROPHENYLPIPERAZINE (META-CPP) TO RATS INDUCES CHANGES IN SEROTONIN RECEPTOR-BINDING, DOPAMINE LEVELS AND LOCOMOTOR-ACTIVITY WITHOUT ALTERING PROLACTIN AND CORTICOSTERONE SECRETION

被引:39
作者
ULRICHSEN, J
PARTILLA, JS
DAX, EM
机构
[1] Neuroendocrinology/Immunology Laboratory, Addiction Research Center, National Institute on Drug Abuse, Baltimore, 21224, MD
关键词
SEROTONIN; META-CHLOROPHENYLPIPERAZINE; RECEPTORS; 5-HT1A; 5-HT1B; 5-HT2; LOCOMOTOR ACTIVITY; NEUROTRANSMITTERS; PROLACTIN; CORTICOSTERONE;
D O I
10.1007/BF02245142
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Meta-chlorophenylpiperazine (mCPP) is a serotonin (5-HT) agonist with antidepressant actions. In order to investigate the effects of chronic mCPP treatment the drug was administered to rats for 15 days (5 mg/kg twice daily). Controls were administered saline. Long-term mCPP treatment led to a 36% increase in [H-3]8-hydroxy-2-(di-n-propylamino)tetralin ([H-3]8-OH-DPAT) binding to 5-HT1a receptors in hippocampus and a 74% decrease in [H-3]ketanserin binding to 5-HT2 receptors in cortex, while (-)[I-125]iodocyanopindolol ([I-125]CYP) binding to 5-HT1b receptors in hypothalamus and striatum was unchanged. In hypothalamus, chronic mCPP treatment decreased the levels of dopamine (DA) but not 5-HT. The usual suppression of locomotor activity induced by acute mCPP administration was less after long-term mCPP treatment. Brain and plasma levels of mCPP following an acute dose were not different between controls and rats previously administered mCPP, suggesting that altered rate of metabolism of the drug did not explain the tolerance to the mCPP-induced decrease in locomotor activity. mCPP-induced prolactin (PRL) and corticosterone release were not changed by previous long-term mCPP administration. Thus, chronic mCPP administration to rats induced alterations in density of 5-HT receptor subtypes, hypothalamic levels of DA and locomotor behavior.
引用
收藏
页码:229 / 235
页数:7
相关论文
共 40 条
[21]   CHARACTERIZATION OF THE 5-HT1B RECOGNITION SITE IN RAT-BRAIN - BINDING-STUDIES WITH (-) [I-125] IODOCYANOPINDOLOL [J].
HOYER, D ;
ENGEL, G ;
KALKMAN, HO .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 118 (1-2) :1-12
[22]  
INVERNIZZI R, 1981, Neurochemistry International, V3, P239, DOI 10.1016/0197-0186(81)90006-1
[23]  
LUCKI I, 1989, J PHARMACOL EXP THER, V249, P155
[24]   EFFECTS OF DAILY ORAL M-CHLOROPHENYLPIPERAZINE IN ELDERLY DEPRESSED-PATIENTS INITIAL EXPERIENCE WITH A SEROTONIN AGONIST [J].
MELLOW, AM ;
LAWLOR, BA ;
SUNDERLAND, T ;
MUELLER, EA ;
MOLCHAN, SE ;
MURPHY, DL .
BIOLOGICAL PSYCHIATRY, 1990, 28 (07) :588-594
[25]   ANALYSIS OF TRAZODONE AND META-CHLOROPHENYLPIPERAZINE IN PLASMA AND BRAIN-TISSUE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
MILLER, RL ;
DEVANE, CL .
JOURNAL OF CHROMATOGRAPHY, 1986, 374 (02) :388-393
[27]  
MONTIGNY C, 1990, SEROTONIN CELL BIOL, P499
[28]   NEURO-ENDOCRINE EFFECTS OF M-CHLOROPHENYLPIPERAZINE, A SEROTONIN AGONIST, IN HUMANS [J].
MUELLER, EA ;
MURPHY, DL ;
SUNDERLAND, T .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 61 (06) :1179-1184
[29]   LIGAND - A VERSATILE COMPUTERIZED APPROACH FOR CHARACTERIZATION OF LIGAND-BINDING SYSTEMS [J].
MUNSON, PJ ;
RODBARD, D .
ANALYTICAL BIOCHEMISTRY, 1980, 107 (01) :220-239
[30]  
OFFORD SJ, 1988, J PHARMACOL EXP THER, V244, P144